Nachrichten zur Agios Pharmaceuticals Aktie

Agios Pharmaceuticals: A Long Overdue Follow Up

…

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism…

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

…

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain…

Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High?

The consensus price target hints at a 26% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this…

Agios Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation

…

Agios Pharmaceuticals, Inc. (AGIO) Q1 2024 Earnings Call Transcript

…

Earnings call: Agios Pharmaceuticals outlines robust pipeline and financial health By Investing.com

Earnings call: Agios Pharmaceuticals outlines robust pipeline and financial health…

Agios Pharmaceuticals (AGIO) Q4 2023 Earnings Call Transcript

…

Agios Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation

…

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -4.88% and 9.84%, respectively, for the quarter ended December 2023. Do…

Agios Pharmaceuticals: Strong Thalassemia Data Makes A Tempting Bull Case

…

Agios Pharmaceuticals (AGIO) Soars 5.2%: Is Further Upside Left in the Stock?

Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…

Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field…

Agios Pharmaceuticals (AGIO) Q3 2023 Earnings Call Transcript

…

Agios Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition

– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in…

Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line

Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus…

Agios and Alnylam sign agreement for siRNA candidate

As per the terms of the exclusive worldwide agreement, Agios will acquire the rights to develop and market Alnylams preclinical…

Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Reports Business Highlights and Second Quarter 2023 Financial Results

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field…

Form 8-K AGIOS PHARMACEUTICALS, For: Aug 03

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: Principal Accounting Officer verkauft Aktien von Agios Pharm im Wert von 32.352$

Washburn, Theodore James Jr. - Vorstand - Tag der Transaktion: 2023-08-01...…

Agios Pharmaceuticals Q2 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Wall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 42.1% in Agios Pharmaceuticals (AGIO).…

Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023

CAMBRIDGE, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field…

Insiderhandel: Chief Legal Officer verkauft Aktien von Agios Pharm im Wert von 48.411$

Burns, James William - Vorstand - Tag der Transaktion: 2023-06-30...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Agios Pharm im Wert von 303.962$

Fouse, Jacqualyn A. - Aufsichtsrat - Tag der Transaktion: 2023-06-30...…

Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat

Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced that the Phase 2 portion of the global Phase 2/3 RISE UP study of mitapivat…

Buzz Dealer Group Appoints Tzur Rupin as CMO; Omer Otmi will take his position as VP of Operations

AGIOS TYCHONAS, Cyprus, June 19, 2023 /PRNewswire/ -- After recently opening an additional office in Cyprus, and initiating a partnership…

Form 8-K AGIOS PHARMACEUTICALS, For: Jun 13

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023

CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field…

Agios Pharmaceuticals (AGIO): Strong Industry, Solid Earnings Estimate Revisions

Agios Pharmaceuticals (AGIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry…

Does Agios Pharmaceuticals (AGIO) Have the Potential to Rally 34.83% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 34.8% in Agios Pharmaceuticals (AGIO).…

Agios Appoints Catherine Owen to Board of Directors

– John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service –...…

Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress

– Agios to Present New Analyses from ACTIVATE, ACTIVATE-T and Long-Term Extension Studies in Adults with PK Deficiency Reinforcing Clinical…

Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales....…

Form 10-Q AGIOS PHARMACEUTICALS, For: Mar 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Pharmaceuticals Q1 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K AGIOS PHARMACEUTICALS, For: Apr 17

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Appoints Jeffrey Capello to Board of Directors

– Board Member Paul Clancy Will Step Down at the End of His Term –...…

Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023

CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field…

Insiderhandel: Aufsichtsrat verkauft Aktien von Agios Pharm im Wert von 373.895$

Schenkein, David P. - Aufsichtsrat - Tag der Transaktion: 2023-04-03...…

Agios Publishes 2023 Environmental, Social and Governance (ESG) Report

– Report Highlights Continued Progress on Patient Access, Health Equity, Diversity and Flexibility –...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Agios Pharm im Wert von 443.000$

Schenkein, David P. - Aufsichtsrat - Tag der Transaktion: 2023-03-27...…

Form 8-K AGIOS PHARMACEUTICALS, For: Mar 02

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Pharmaceuticals (AGIO) Moves to Strong Buy: Rationale Behind the Upgrade

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the companys earnings…

Agios (AGIO) Q4 Earnings Beat Estimates, Revenues Miss

Agios (AGIO) reports mixed fourth-quarter results as earnings beat estimates and revenues miss the same....…

Agios Pharmaceuticals (AGIO) Beats Q4 Earnings Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 142.14% and 2.49%, respectively, for the quarter ended December 2022. Do…

Agios Reports Fourth Quarter and Full Year 2022 Financial Results

– Completed Enrollment in Phase 2 RISE UP Study of PYRUKYND® (mitapivat) in Sickle Cell Disease –...…